Fimepinostat (CUDC‐907) in patients with relapsed/refractory diffuse large B cell and high‐grade B‐cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses - Landsburg, Daniel J.; Barta, Stefan K.; Ramchandren, Radhakrishnan; Batlevi, Connie; Iyer, Swaminathan; Kelly, Kevin; Micallef, Ivana N.; Smith, Sonali M.; Stevens, Don A.; Alvarez, Mariano; Califano, Andrea; Shen, Yao; et al. (British journal of haematology, 2021)
Keywords: B-cell lymphoma; biomarker; Biomarkers; Biomarkers, Tumor - analysis; Clinical trials; Copy number; diffuse large B‐cell lymphoma; Female; Gene rearrangement; Hematology; Histone deacetylase; histone deacetylase inhibitor; Histone Deacetylase Inhibitors - administration & dosage; Histone Deacetylase Inhibitors - therapeutic use; Humans; Kinases; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - genetics; Lymphoma, Non-Hodgkin - drug therapy; Lymphoma, Non-Hodgkin - genetics; Male; Middle Aged; Morpholines - administration & dosage; Morpholines - therapeutic use; MYC; Myc protein; Patients; phosphatidylinositol 3‐kinase inhibitor; Phosphoinositide-3 Kinase Inhibitors - administration & dosage; Phosphoinositide-3 Kinase Inhibitors - therapeutic use; Predictive Value of Tests; Proteins; Proto-Oncogene Proteins c-myc - genetics; Pyrimidines - administration & dosage; Pyrimidines - therapeutic use; Recurrence; Safety; Treatment Outcome; phosphatidylinositol 3-kinase inhibitor; diffuse large B-cell lymphoma; biomarker; MYC; histone deacetylase inhibitor